FDA Brief

Warning letters Drugs

FDA warning letter to

Zen Enterprises LLC

LowIssued Apr 18, 2024Posted Apr 23, 2024Center for Drug Evaluation and Research | CDER

Zen Enterprises failed to correct drug listing files that named a manufacturer not involved in making its balms and hand sanitizers.

What happened

FDA reviewed the drug listing files Zen Enterprises submitted through its electronic Drug Registration and Listing System (eDRLS) for four products. In a December 15, 2022 response to an FDA records request, the firm confirmed that the manufacturer named in those listings, Dr. Sankunni's Ayurvedic Research Foundation Private Ltd., was not making the drugs, yet the listings were never updated. FDA sent a listing deficiency letter on December 4, 2023 and a data removal notice on January 18, 2024, and the products were removed from FDA's Online NDC Directory.

What FDA found

  1. The firm did not keep its drug listing information complete and accurate, which the law requires.

    Section 510(j) of the FD&C Act, 21 U.S.C. 360(j); 21 CFR Part 207
  2. The listing files named a manufacturer that was not actually making the drugs.

    21 CFR 207.49(a)(12)(i)
  3. The listing files did not name every establishment where the drugs are made, with its identifier and type of operation.

    21 CFR 207.49(a)(12)(ii)
  4. Because the products were not properly listed, FDA treats them as misbranded drugs.

    Section 502(o) of the FD&C Act, 21 U.S.C. 352(o)
  5. Failing to meet listing duties is a prohibited act.

    Section 301(p) of the FD&C Act, 21 U.S.C. 331(p)
  6. Shipping misbranded drugs across state lines is prohibited.

    Section 301(a) of the FD&C Act, 21 U.S.C. 331(a)

What FDA wants

Within 15 working days of receiving the letter, Zen Enterprises must write to FDA describing the specific steps it has taken to fix the listings and prevent repeat problems, with supporting documents. If the work cannot be finished in that time, the firm must explain the delay and say when it will be done.

Who should pay attention

  • firms whose drug listings name contract manufacturers that may have changed
  • labelers and distributors of balms and hand sanitizers sold under their own name
  • regulatory staff who maintain eDRLS registration and listing files

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk